ACTG398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN COM

ACTG398 安普那韦作为 COM 中双蛋白酶抑制剂方案的一部分

• 批准号: 6306583
• 负责人: GILDON N BEALL
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6306583
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clinical research; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; protease inhibitor

To evaluate strategies for treatment of HIV infection in patient-subjects who have failed usual treatment.Triple drug, highly active antiretroviral (HAART) treatment is now being used very widely but it is failing in some subjects. This study will evaluate several treatment strategies in subjects that have failed one to three PI's. The novel treatment agents to be used are not available as licensed drugs, although some are available through so-called "expanded access" mechanisms.

评价常规治疗失败的HIV感染者的治疗策略，三联药物高效抗逆转录病毒（HAART）治疗目前被广泛使用，但在某些受试者中失败。本研究将评估一到三次PI失败的受试者的几种治疗策略。将使用的新型治疗剂并不作为许可药品提供，尽管有些可通过所谓的“扩大获取”机制获得。